Waters Corp reported fourth‑quarter 2025 sales of $932.4 million, a 7% year‑over‑year increase, and non‑GAAP earnings per share of $4.53, up 10% from the same period a year earlier. The company beat analyst consensus by $0.02 per share, with revenue exceeding the $928.09 million estimate. The beat was driven by robust demand in the instrument and consumable businesses, strong pricing power in the chemistry segment, and disciplined cost management that helped offset modest inflationary pressures.
Full‑year 2025 sales totaled $3.165 billion, up 7% from $2.958 billion in 2024, while adjusted EPS rose to $13.13 from $11.86, an 11% increase. Recurring revenue grew 10% YoY, supported by an accelerating instrument replacement cycle and higher mix of high‑margin consumables. Gross margin expanded to 61.1% and adjusted operating margin reached 35.2%, reflecting both pricing strength and operational leverage as the company scales its platform portfolio.
Segment analysis shows that the instrument and consumable businesses were the primary growth engines. Sales of the Alliance iS HPLC and Xevo TQ Absolute platforms increased significantly, and the chemistry segment grew 12% in constant currency. Management noted that inflation and foreign‑exchange headwinds were partially offset by higher pricing in the chemistry and materials science segments, allowing the company to maintain margin expansion.
Waters guided for 2026 sales growth of 5.5%–7.0% on an organic constant‑currency basis and adjusted EPS of $14.30–$14.50. The guidance reflects a cautious outlook as the company integrates the recently completed acquisition of Becton, Dickinson’s Biosciences & Diagnostic Solutions business. Management expects a 28.1% adjusted operating margin in 2026, an improvement of more than 100 basis points over the 2025 margin, signaling confidence in synergy realization while acknowledging integration costs.
The acquisition, completed on February 9 2026, was valued at $17.5 billion and structured as a reverse Morris Trust, giving BD shareholders 39.2% of the combined entity. The deal expands Waters’ scale, adds a broad diagnostics portfolio, and is expected to double its addressable market. CEO Udit Batra emphasized that the combination will “bring together world‑class scientific expertise across chemistry, physics, and biology” and that the company is focused on delivering long‑term value through integrated solutions.
Investors reacted cautiously to the results, focusing on the conservative 2026 guidance and the integration risks associated with the BD acquisition. While the earnings beat and margin expansion underscored strong execution, the market’s attention to forward‑looking metrics highlights the importance of the company’s post‑merger strategy and its impact on future growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.